These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 26754254)

  • 1. Safety Evaluation of Dry Powder Formulations by Direct Dispersion onto Air-Liquid Interface Cultured Cell Layer.
    Asai A; Okuda T; Yamauchi T; Sugiura Y; Okamoto H
    Biol Pharm Bull; 2016; 39(3):368-77. PubMed ID: 26754254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug Permeation Characterization of Inhaled Dry Powder Formulations in Air-Liquid Interfaced Cell Layer Using an Improved, Simple Apparatus for Dispersion.
    Asai A; Okuda T; Sonoda E; Yamauchi T; Kato S; Okamoto H
    Pharm Res; 2016 Feb; 33(2):487-97. PubMed ID: 26490362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of l-Carnitine and l-Carnitine HCL salt for targeted lung treatment of pulmonary hypertension (PH) as inhalation aerosols: Design, comprehensive characterization, in vitro 2D/3D cell cultures, and in vivo MCT-Rat model of PH.
    Acosta MF; Muralidhran P; Abrahamson MD; Grijalva CL; Carver M; Tang H; Klinger C; Fineman JR; Black SM; Mansour HM
    Pulm Pharmacol Ther; 2020 Dec; 65():101998. PubMed ID: 33556627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel dry powder inhalation system based on dispersion of lyophilisates.
    Claus S; Schoenbrodt T; Weiler C; Friess W
    Eur J Pharm Sci; 2011 May; 43(1-2):32-40. PubMed ID: 21440061
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Physicochemical characterization and aerosol dispersion performance of organic solution advanced spray-dried microparticulate/nanoparticulate antibiotic dry powders of tobramycin and azithromycin for pulmonary inhalation aerosol delivery.
    Li X; Vogt FG; Hayes D; Mansour HM
    Eur J Pharm Sci; 2014 Feb; 52():191-205. PubMed ID: 24215736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of an inhaled controlled release voriconazole dry powder formulation for the treatment of respiratory fungal infection.
    Arora S; Haghi M; Loo CY; Traini D; Young PM; Jain S
    Mol Pharm; 2015 Jun; 12(6):2001-9. PubMed ID: 25923171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heat-Stable Dry Powder Oxytocin Formulations for Delivery by Oral Inhalation.
    Fabio K; Curley K; Guarneri J; Adamo B; Laurenzi B; Grant M; Offord R; Kraft K; Leone-Bay A
    AAPS PharmSciTech; 2015 Dec; 16(6):1299-306. PubMed ID: 25776985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Feasibility of spray drying bacteriophages into respirable powders to combat pulmonary bacterial infections.
    Vandenheuvel D; Singh A; Vandersteegen K; Klumpp J; Lavigne R; Van den Mooter G
    Eur J Pharm Biopharm; 2013 Aug; 84(3):578-82. PubMed ID: 23353012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of particle properties in pharmaceutical powder inhalation formulations.
    Chew NY; Chan HK
    J Aerosol Med; 2002; 15(3):325-30. PubMed ID: 12396421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. L-Leucine as an excipient against moisture on in vitro aerosolization performances of highly hygroscopic spray-dried powders.
    Li L; Sun S; Parumasivam T; Denman JA; Gengenbach T; Tang P; Mao S; Chan HK
    Eur J Pharm Biopharm; 2016 May; 102():132-41. PubMed ID: 26970252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Powder, capsule and device: An imperative ménage à trois for respirable dry powders.
    Schoubben A; Blasi P; Giontella A; Giovagnoli S; Ricci M
    Int J Pharm; 2015 Oct; 494(1):40-8. PubMed ID: 26255220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Formulation and in vitro evaluation of highly dispersive insulin dry powder formulations for lung administration.
    Depreter F; Amighi K
    Eur J Pharm Biopharm; 2010 Nov; 76(3):454-63. PubMed ID: 20797437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advanced spray-dried design, physicochemical characterization, and aerosol dispersion performance of vancomycin and clarithromycin multifunctional controlled release particles for targeted respiratory delivery as dry powder inhalation aerosols.
    Park CW; Li X; Vogt FG; Hayes D; Zwischenberger JB; Park ES; Mansour HM
    Int J Pharm; 2013 Oct; 455(1-2):374-92. PubMed ID: 23820131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low powder mass filling of dry powder inhalation formulations.
    Eskandar F; Lejeune M; Edge S
    Drug Dev Ind Pharm; 2011 Jan; 37(1):24-32. PubMed ID: 20738180
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Physical characteristics and aerosolization performance of insulin dry powders for inhalation prepared by a spray drying method.
    You Y; Zhao M; Liu G; Tang X
    J Pharm Pharmacol; 2007 Jul; 59(7):927-34. PubMed ID: 17637186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dry powder inhalation: past, present and future.
    de Boer AH; Hagedoorn P; Hoppentocht M; Buttini F; Grasmeijer F; Frijlink HW
    Expert Opin Drug Deliv; 2017 Apr; 14(4):499-512. PubMed ID: 27534768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of a dry powder insufflation device with application in in vitro cell-based assays in the context of respiratory delivery.
    Pontes JF; Diogo HP; Conceição E; Almeida MP; Borges Dos Santos RM; Grenha A
    Eur J Pharm Sci; 2024 Jun; 197():106775. PubMed ID: 38643941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new Pharmaceutical Aerosol Deposition Device on Cell Cultures (PADDOCC) to evaluate pulmonary drug absorption for metered dose dry powder formulations.
    Hein S; Bur M; Schaefer UF; Lehr CM
    Eur J Pharm Biopharm; 2011 Jan; 77(1):132-8. PubMed ID: 20951200
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Air permeability of powder: a potential tool for Dry Powder Inhaler formulation development.
    Le VN; Robins E; Flament MP
    Eur J Pharm Biopharm; 2010 Nov; 76(3):464-9. PubMed ID: 20854906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insights into the roles of carrier microstructure in adhesive/carrier-based dry powder inhalation mixtures: Carrier porosity and fine particle content.
    Shalash AO; Molokhia AM; Elsayed MM
    Eur J Pharm Biopharm; 2015 Oct; 96():291-303. PubMed ID: 26275831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.